Group 1 - The China Securities Regulatory Commission has issued a notice regarding Hangzhou Deshi Biotechnology Co., Ltd.'s overseas issuance and the "full circulation" of unlisted shares in China, with plans to issue up to 31.04 million overseas listed ordinary shares on the Hong Kong Stock Exchange [1] - A total of 27 shareholders intend to convert a combined 80.88 million unlisted shares into overseas listed shares for circulation on the Hong Kong Stock Exchange [1][4][5] Group 2 - Deshi Biotechnology focuses on the medical imaging AI industry, with its proprietary iMedImageTM model supporting 19 types of medical imaging modalities and covering over 90% of clinical medical imaging scenarios [3] - The iMedImageTM model is recognized as the world's largest general-purpose medical imaging base model and has been successfully commercialized, being the first commercialized cross-modal medical imaging base model [3]
德适生物港股IPO及境内未上市股份“全流通”获中国证监会备案
Zhi Tong Cai Jing·2026-01-05 12:18